:format(webp))
Over the past few years, Australia has emerged as a premier global hub, particularly for early-phase clinical trials, attracting biotechnology and pharmaceutical sponsors from all over the world.
In this video, QuickSTAT's Greg Walters breaks down the key factors fueling this remarkable growth. Discover why international sponsors are increasingly looking to the Asia-Pacific region and how QuickSTAT’s specialized logistics network supports the seamless execution of these critical trials.
How Australia’s streamlined Clinical Trial Notification (CTN) scheme enables sponsors to initiate trials and get the first patient dosed in just a few months - significantly faster than standard US or EU timelines.
The impact of Australia’s robust R&D tax incentives and dedicated funding initiatives that drastically lower financial barriers for foreign biopharma companies.
A look at the country’s elite network of clinical trial sites, highly trained medical investigators, and top-tier data quality that major global regulators seamlessly accept.
How QuickSTAT navigates Australia's strict biosecurity, customs regulations, and specialized cold chain requirements to keep clinical supply chains moving flawlessly.
Loading iFrame
Press play to get started.
Speeding up the study start-up phase means life-saving therapies can complete clinical evaluation and reach the patients who need them much sooner.
Data generated across Australia's diverse participant demographics is inspection-ready and routinely accepted by major bodies like the FDA and EMA.
With specialized, time-critical materials like advanced therapeutics traveling across massive global distances, having a dedicated logistics partner in the APAC region minimizes transit risks and guards against temperature deviations.